Financial News

Csl Ltd ADR (OP: CSLLY )

89.30 +0.57 (+0.64%)

Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Csl Ltd ADR

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

October 07, 2024

Via Benzinga

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

September 30, 2024

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...

Via Benzinga

Exposures COVID-19

FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

April 26, 2024

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.

Via Benzinga

Exposures Product Safety

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

December 13, 2023

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Via Benzinga

Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines

November 02, 2022

Via Benzinga

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks

August 17, 2022

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

Exposures Product Safety

5 Diverse Medical Stocks To Buy For 2023 And Beyond

April 08, 2023

Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and...

Via Talk Markets

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories

March 20, 2023

Reuters

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'

March 20, 2023

Via Benzinga

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment

February 21, 2023

Via Benzinga

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults

November 23, 2022

Via Benzinga

Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?

November 02, 2022

The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.

Via InvestorPlace

Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder

August 22, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021

December 14, 2021

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify...

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Financial News

Csl Ltd ADR (OP: CSLLY )

Headline News about Csl Ltd ADR

Popular Pages